stockrowBillionToOne, Inc.
BLLN Healthcare Diagnostics & Research
BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024.
- Revenue
- +47.2%
- EPS
- +164.3%
- Free cash flow
- +9.25%
- Total debt
- +60.6%
Quarter to September 2026, against a year earlier
Follow BLLN
Alert me
BillionToOne, Inc. (BLLN) Price to free cash flow
As of 5 November 2026, BillionToOne, Inc. (BLLN) trades at a price to free cash flow of 156×. Over the past ten years it has ranged from 0.0× (December 2025) to 210× (August 2026); the current reading is higher than 74% of that period. That is above the Diagnostics & Research industry median of 33.5× and above the Healthcare sector median of 21.1×.
Price to free cash flow, daily
Embed this chart
Annual newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2025 | 82.7× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| Sep 2026 | 148× | (11.57%) |
| Jun 2026 | 168× | 22.17% |
| Mar 2026 | 137× | 66.15% |
| Dec 2025 | 82.7× | — |
| 4 more quarters | Free account |
Against its own ten years
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| NEO NeoGenomics, Inc. compare | n/m |
| GRAL GRAIL, Inc. compare | n/m |
| ADPT Adaptive Biotechnologies Corporation compare | n/m |
| VCYT Veracyte, Inc. compare | 12.0× |
| QGEN QIAGEN N.V. compare | 23.8× |
| SHC Sotera Health Company compare | 33.5× |
| CDNA CareDx, Inc. compare | 68.9× |
| BLLN BillionToOne, Inc. | 156× |
| RDNT RadNet, Inc. compare | 189× |
| Diagnostics & Research industry median | 33.5× |
| Healthcare sector median | 21.1× |
| Market median | 14.1× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))
More on BLLN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement